Matthew Herper points to a case where a four-month FDA delay contributed to a small biotech closing, underscoring how regulatory timelines can be existential for early-stage companies.
How a four-month FDA delay forced a small biotech company to close its doors
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare